Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$146.27
pos +0.00
+0.00%
Today's Range: 144.02 - 148.10 | BMRN Avg Daily Volume: 1,302,000
Last Update: 07/31/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 61.80%
Open: $0.00
Previous Close: $144.56
52 Week Range: $61.03 - $151.75
Oustanding Shares: 160,336,762
Market Cap: 23,178,282,315
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 11 11
Moderate Buy 1 1 1 1
Hold 3 3 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.47 1.36 1.47
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -135.10
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-135.10 0.00 25.63
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
30.54% 136.61% 272.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.90 0.70 0.19
Net Income 0.00 1.49 0.00
EPS 0.00 0.92 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.75B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $-0.53 $-0.57 $-2.15 $-1.54
Number of Analysts 11 11 12 12
High Estimate $-0.30 $-0.42 $-1.57 $-0.93
Low Estimate $-0.64 $-0.64 $-2.53 $-2.45
Prior Year $-0.19 $-0.16 $-0.77 $-2.15
Growth Rate (Year over Year) -180.38% -257.39% -179.00% 28.32%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Sebastian Silva

 | Aug 2, 2015 | 7:39 PM EDT

Coal and renewables could both react as political and legal battles ensue.

By

Robert Lang

 | Jul 10, 2015 | 10:00 AM EDT

BioMarin's chart has a well-defined uptrend line and shows great relative strength.

By

Robert Lang

 | Jun 22, 2015 | 10:00 AM EDT

I like BioMarin because it has more upside and solid Relative Strength.

bearishBiomarin downgraded at Baird

Jun 19, 2015 | 7:04 AM EDT

BMRN was downgraded from Outperform to Neutral, Robert Baird said. Valuation call, based on a $133 price target.  

bullishBiomarin rated new Overweight at Barclays

Jun 5, 2015 | 7:18 AM EDT

BMRN was initiated with an Overweight rating, Barclays said. $150 price target. Company has strong operating momentum with major pipeline opportunities. 

By

Dan Fitzpatrick

 | May 27, 2015 | 5:00 PM EDT

Sector may not be as bulletproof as we thought.

By

Jim Cramer

 | May 18, 2015 | 12:19 PM EDT

Many of these stocks are off to the races.

By

Jim Cramer

 | May 4, 2015 | 11:51 AM EDT

And it's not the favorable macroeconomic climate.

By

Jim Cramer

 | Mar 30, 2015 | 5:39 AM EDT

An answer to those asking me what's worth buying.

By

Jim Cramer

 | Mar 27, 2015 | 12:00 PM EDT

You can't help but feel better about both groups.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.